Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05344274 · ClinicalTrials.gov registry record · Phase 4
Retinal Blood Flow and Autoregulation
A Phase 4 study of Glaucoma, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 4
- Study locations
NCT05344274: Recruiting Phase 4 study of Glaucoma, sponsored by University of Maryland, Baltimore.
NCT05344274 is a Phase 4 study of Glaucoma that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 90 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05344274, a Phase 4 study of Glaucoma, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.
Primary Outcome
Autoregulation of flow is measured by the percent flow difference in flow between air and oxygen
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Indocyanine Green Angiography
- BIOLOGICAL Isocapnic Oxygen
- DIAGNOSTIC_TEST Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)
Study Locations (4)
Maryland
- University of Maryland Faculty Physicians, Inc - Baltimore
- University of Maryland Medical Center - Baltimore
- University of Maryland, Baltimore - Baltimore
- Food and Drug Administration (FDA) - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-05-23 |
| Est. Completion | 2027-09 |
| Phase | Phase 4 |
What NCT05344274 shows while recruiting
NCT05344274 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which Indocyanine Green Angiography is the first listed.
NCT05344274 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05344274 about?
NCT05344274 is a clinical study titled "Retinal Blood Flow and Autoregulation". The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.
What is the current status of trial NCT05344274?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2022-05-23. Estimated completion is 2027-09.
What conditions does trial NCT05344274 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT05344274?
The interventions under investigation include: Indocyanine Green Angiography (DIAGNOSTIC_TEST), Isocapnic Oxygen (BIOLOGICAL), Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05344274?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05344274 being conducted?
This trial has 4 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05344274's enrollment target sits among peer trials
90 48th of 92 higher than 45 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI